Announcements Trials
Browse Landscape

Phase

Phase 1 19Phase 2 3Phase 2/3 2Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Neoplasms 3Pancreatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Interventional × budigalimab × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

AbbVie

Phase 2 Active not recruiting
130 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

AbbVie

Phase 2 Active not recruiting
150 enrolled
Genitourinary

Carcinoma, Transitional Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡